seekingalpha.com
Heron Therapeutics, Inc. (HRTX) Q4 2025 Earnings Call Transcript
Heron Therapeutics, Inc. (HRTX) Q4 2025 Earnings Call Transcript
Heron Therapeutics, Inc.HRTXNASDAQ
Loading
Latest News
Loading news...
zacks.com
Heron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
globenewswire.com
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results
– ZYNRELEF ® and APONVIE ® Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise – Achieved $154.9 Million in 2025 Net Revenue– Issues Full-Year 2026 Net Revenue Guidance of $173 to $183 Million and Adjusted EBITDA of $10 to $20 Million CARY, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended December 31, 2025, and highlighted recent corporate updates.
seekingalpha.com
Heron: Near The Bottom Of A Trading Range Despite Positives
HRTX has reported preliminary Q4'25 net revenues, with Zynrelef experiencing a breakout quarter. Aponvie sales are also still growing, with the acute care franchise being able to offset declines in the oncology care franchise. HRTX recently dealt with its 2026 convertible notes, although the company does now have debt maturing in 2030 and 2031.
globenewswire.com
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
CARY, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Thursday, February 26, 2026, at 8:30 a.m. ET to report fourth quarter and full year 2025 financial results and discuss recent business highlights.
defenseworld.net
New York State Common Retirement Fund Buys 816,671 Shares of Heron Therapeutics, Inc. $HRTX
New York State Common Retirement Fund raised its stake in Heron Therapeutics, Inc. (NASDAQ: HRTX) by 46.4% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,576,716 shares of the biotechnology company's stock after purchasing an additional 816,671 shares
defenseworld.net
Heron Therapeutics (NASDAQ:HRTX) & Enliven Therapeutics (NASDAQ:ELVN) Head to Head Contrast
Heron Therapeutics (NASDAQ: HRTX - Get Free Report) and Enliven Therapeutics (NASDAQ: ELVN - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Insider and Institutional Ownership 80.0% of Heron
globenewswire.com
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth
CARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth quarter and full-year 2025 net revenue. “We are encouraged by the growth in Q4 2025, driven in particular by the momentum in our Acute Care franchise with ZYNRELEF® and APONVIE®,” said Craig Collard, Chief Executive Officer of Heron.
defenseworld.net
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Average Recommendation of “Hold” from Analysts
Heron Therapeutics, Inc. (NASDAQ: HRTX - Get Free Report) has been assigned a consensus rating of "Hold" from the five brokerages that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company.
defenseworld.net
Congress Park Capital LLC Acquires 621,908 Shares of Heron Therapeutics, Inc. $HRTX
Congress Park Capital LLC lifted its holdings in shares of Heron Therapeutics, Inc. (NASDAQ: HRTX) by 27.4% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,890,157 shares of the biotechnology company's stock after purchasing an additional 621,908 shares
globenewswire.com
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)
CARY, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced the inclusion of APONVIE® (aprepitant) injectable emulsion in the newly released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting: Executive Summary and Full Report as published in Anesthesia and Analgesia (collectively, the “PONV Guidelines”).
defenseworld.net
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives $4.50 Average Price Target from Brokerages
Heron Therapeutics, Inc. (NASDAQ: HRTX - Get Free Report) has been given an average rating of "Hold" by the five analysts that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average
seekingalpha.com
Heron Therapeutics, Inc. (HRTX) Q3 2025 Earnings Call Transcript
Heron Therapeutics, Inc. ( HRTX ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Melissa Jarel - Executive Director of Legal Craig Collard - CEO & Director Mark Hensley - Executive VP & COO Ira Duarte - Executive VP & CFO Kevin Warner - Senior Vice President of Medical Affairs Strategy & Engagement William Forbes - Executive VP & Chief Development Officer Conference Call Participants Carl Byrnes - Northland Capital Markets, Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Serge Belanger - Needham & Company, LLC, Research Division Presentation Operator Good day, and thank you for standing by.
zacks.com
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zacks.com
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.03 per share a year ago.
globenewswire.com
Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress
Generated Q3 2025 Net Revenue of $38.2 million and year-to-date revenue of $114.3 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163 million and adjusted EBITDA of $9.0 - $13.0 million ZYNRELEF ® Net Revenue grew 49% in Q3 2025, as compared to Q3 2024, continuing momentum with the launch of the Vial Access Needle (VAN) and enhanced incentive program with key distributors APONVIE ® Net Revenue grew 173% in Q3 2025, as compared to Q3 2024, supported by increased adoption and momentum building with the newly launched dedicated sales team in Q3 2025 CARY, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three and nine months ended September 30, 2025 and recent corporate updates.
globenewswire.com
Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cusack has extensive experience in matters related to corporate finance, investment management, and corporate governance. Mr. Cusack was appointed to the Board pursuant to the Cooperation Agreement entered into between the Company and Rubric Capital Management LP, dated as of August 8, 2025.
globenewswire.com
Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
CARY, N.C., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, November 4, 2025, at 8:30 a.m. ET to report third quarter 2025 financial results and discuss recent business highlights.
prnewswire.com
Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value
CARY, N.C. , Aug. 15, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that its Board of Directors (the "Board") has adopted a Section 382 rights plan (the "Rights Plan") designed to protect the availability and significant potential value of the Company's net operating loss carryforwards ("NOLs") and other tax attributes, which may be used to offset future taxable income. The Board unanimously approved the adoption of the Rights Plan.
seekingalpha.com
Heron Therapeutics, Inc. (HRTX) Q2 2025 Earnings Call Transcript
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q2 2025 Earnings Conference Call August 8, 2025 8:30 AM ET Company Participants Craig Alexander Collard - CEO & Director Ira Duarte - Executive VP & CFO Mark E. Hensley - Executive VP & COO Melissa Jarel - Executive Director of Legal Conference Call Participants Brandon Richard Folkes - H.C.